shares in elan and biogen idec plunged on monday as the firms suspended sales of new multiple sclerosis drug tysabri after a patients death in the uselan once the biggest firm on the irish stock exchange was also expected to receive a boost from the new producton the new york stock exchange shares in irelandbased elan lost 70 while us partner biogen idec shed 43 shares in uk pharmaceutical firm phytopharm closed down 1984 at 1515 pence on the london stock exchange on monday after it said a partner was set to pull out of a deal on an experimental alzheimers disease treatmenttysabri was approved for use in the us last november and was widely tipped to become the worlds leading multiple sclerosis treatmentthe cases cited involved the use of both tysabri and avonex biogen idecs existing multiple sclerosis drugmost of the value in the company was in tysabri said ian hunter at goodbody stockbrokers in dublin
